---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000574"
form_type: "8-K"
ticker: null
cik: "0001783032"
company_name: "Elevation Oncology, Inc."
filed_at: "2025-01-31T23:59:59+00:00"
generated_at: "2026-05-27T04:46:29.238133+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Elevation Oncology CSO David Dornan resigns effective Feb 17, 2025; to assist as consultant

## Summary
- Chief Scientific Officer David Dornan, Ph.D., resigns effective February 17, 2025.
- Resignation is not based on any disagreement with the company on any matter.
- Dornan will continue to assist Elevation Oncology as a consultant to support transition.

## SEC filing metadata
- accession: 0001558370-25-000574
- form_type: 8-K
- cik: 0001783032
- company_name: Elevation Oncology, Inc.
- filed_at: 2025-01-31T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783032/000155837025000574/0001558370-25-000574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783032/000155837025000574/elev-20250129x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000574
- JSON: https://secwatch.observer/filing/0001558370-25-000574.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000574.txt

## Key facts
- Executive change
  David Dornan resigned as Chief Scientific Officer at Elevation Oncology, Inc..
  - Action: resigned
  - Role: Chief Scientific Officer
  source text: On January 29, 2025, David Dornan, Ph.D., Chief Scientific Officer of Elevation Oncology, Inc. (the “Company”), informed the Company that he is resigning to pursue another opportunity, effective February 17, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783032/000155837025000574/0001558370-25-000574-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.